FOR IMMEDIATE RELEASE
ACS News Service Weekly PressPac: July 21, 2021
New method predicts COVID-19 severity, could help with hospital triage
Analytical Chemistry
During the height of the pandemic, some hospitals were overwhelmed with patients seeking treatment for COVID-19. This situation could happen again during future outbreaks, especially with SARS-CoV-2 variants of concern on the rise. Now, researchers reporting in ACS’Ì�Analytical ChemistryÌýhave developed a blood test to predict which people infected with COVID-19 Ìýare most likely to experience serious symptoms, which could help health care workers prioritize patients for hospitalization and intensive care.
Although many people who contract COVID-19 have either no symptoms or mild ones, some require intensive care for pneumonia with acute respiratory distress syndrome. Risk factors for severe disease include older age, heart disease, cancer and diabetes, but these characteristics alone are not sufficient to predict which patients will become the sickest. Measuring levels of certain proteins or metabolites in the blood could help, but these tests are often slow, complicated or expensive. For more effective triage of COVID-19 patients at hospitals, Michelle Hill, Sanjeeva Srivastava and colleagues aimed to develop an easy-to-use method that could quickly and cost-effectively predict COVID-19 severity.
To measure changes in blood biochemistry that occur with severe COVID-19, the researchers chose a technique called attenuated total reflectance Fourier transform infrared spectroscopy (ATR-FTIR), which has been tested previously as a COVID-19 diagnostic tool. Two regions of FTIR spectra from 128 patient plasma samples showed small but observable differences between those with severe and non-severe COVID-19. Using these data together with clinical information about patients, the researchers developed a statistical model to predict COVID-19 severity. They found that the best predictor was whether the patient had diabetes, followed by the two regions in the FTIR spectra. Adding the FTIR data to the model improved the sensitivity for detecting severe disease in a different set of 30 patients from 41.2% to 94.1%, but reduced the specificity from 84.6% to 69.2%, compared with the clinical factors alone. This means that the new test was more likely to identify severe cases, but it also had a higher rate of false positives, than the clinical data alone. Although the strategy needs to be tested in larger numbers of patients, it shows promise as a rapid, simple and economic triaging test for hospitals, the researchers say.
The authors acknowledge funding from theÌý, the Industrial Research and Consultancy Centre of the Indian Institute of Technology Bombay, theÌý, theÌýÌýand theÌý, as well as instrument support from.
Ìý
Ìý
###
The American Chemical Öйú365betÖÐÎĹÙÍø (ACS) is a nonprofit organization founded in 1876 and chartered by the U.S. Congress. ACS is committed to improving all lives through the transforming power of chemistry. Its mission is to advance scientific knowledge, empower a global community and champion scientific integrity, and its vision is a world built on science. The Öйú365betÖÐÎĹÙÍø is a global leader in promoting excellence in science education and providing access to chemistry-related information and research through its multiple research solutions, peer-reviewed journals, scientific conferences, e-books and weekly news periodicalÌýChemical & Engineering News. ACS journals are among the most cited, most trusted and most read within the scientific literature; however, ACS itself does not conduct chemical research. As a leader in scientific information solutions, its CAS division partners with global innovators to accelerate breakthroughs by curating, connecting and analyzing the world’s scientific knowledge. ACSâ€� main offices are in Washington, D.C., and Columbus, Ohio.
Registered journalists can subscribe to the to access embargoed and public science press releases. For media inquiries, contact newsroom@acs.org.
Note: ACS does not conduct research but publishes and publicizes peer-reviewed scientific studies.
Media Contact
ACS Newsroom
newsroom@acs.org
###
La sociedad American Chemical Öйú365betÖÐÎĹÙÍø (ACS) es una organización sin fines de lucro fundada en 1876 y aprobada por el Congreso de los Estados Unidos. La ACS se ha comprometido a mejorar la vida de todas las personas mediante la transformación del poder de la quÃmica. Su misión es promover el conocimiento cientÃfico, empoderar a la comunidad global y defender la integridad cientÃfica, y su visión es un mundo construido basándose en la ciencia. La Sociedad es lÃder mundial en la promoción de la excelencia en la educación cientÃfica y en el acceso a información e investigación relacionadas con la quÃmica a través de sus múltiples soluciones de investigación, publicaciones revisadas por expertos, conferencias cientÃficas, libros electrónicos y noticias semanales periódicas de Chemical & Engineering News. Las revistas de la ACS se encuentran entre las más citadas, las más fiables y las más leÃdas en la literatura cientÃfica; sin embargo, la propia ACS no realiza investigación quÃmica. Como lÃder en soluciones de información cientÃfica, su división CAS se asocia con innovadores internacionales para acelerar los avances mediante la preservación, la conexión y el análisis de los conocimientos cientÃficos del mundo. Las sedes principales de la ACS se encuentran en Washington, D.C., y Columbus, Ohio.
Los periodistas registrados pueden suscribirse al en EurekAlert! para acceder a comunicados de prensa públicos y retenidos.Ìý Para consultas de los medios, comunÃquese con newsroom@acs.org.
Nota: ACS no realiza investigaciones, pero publica y divulga estudios cientÃficos revisados por expertos.â€�
;void(0);){kind=link}